Registration Strip Icon for pro Trade like a pro: Leverage real-time discussions and market-moving ideas to outperform.

GANX

Gain Therapeutics (GANX)

Gain Therapeutics Inc
Date:
Sort by:
 Showing the most relevant articles for your search:NASDAQ:GANX
DateTimeSourceHeadlineSymbolCompany
07/12/20245:24PMEdgar (US Regulatory)Form 8-K - Current reportNASDAQ:GANXGain Therapeutics Inc
07/09/20245:18PMEdgar (US Regulatory)Form 8-K - Current reportNASDAQ:GANXGain Therapeutics Inc
06/28/20244:39PMGlobeNewswire Inc.Gain Therapeutics to Hold a Business Update Conference Call on July 1, 2024NASDAQ:GANXGain Therapeutics Inc
06/27/20244:08PMGlobeNewswire Inc.Gain Therapeutics, Inc. Appoints Gene Mack as Interim CEONASDAQ:GANXGain Therapeutics Inc
06/27/20248:35AMGlobeNewswire Inc.Gain Therapeutics Presents GT-02287 Data at Federation of European Neuroscience Societies (FENS) Forum 2024 Demonstrating Improvements in Cognitive Performance in a Preclinical Model of GBA1 Parkinson’s diseaseNASDAQ:GANXGain Therapeutics Inc
06/25/20247:00AMGlobeNewswire Inc.Gain Therapeutics to Participate at H.C. Wainwright 5th Annual Neuro Perspectives Virtual ConferenceNASDAQ:GANXGain Therapeutics Inc
06/17/20248:30AMEdgar (US Regulatory)Form 424B5 - Prospectus [Rule 424(b)(5)]NASDAQ:GANXGain Therapeutics Inc
06/14/20244:40PMEdgar (US Regulatory)Form 8-K - Current reportNASDAQ:GANXGain Therapeutics Inc
06/13/20249:00PMGlobeNewswire Inc.Gain Therapeutics Announces Pricing of $11.0 Million Public OfferingNASDAQ:GANXGain Therapeutics Inc
06/13/20244:44PMGlobeNewswire Inc.Gain Therapeutics Announces Proposed Public OfferingNASDAQ:GANXGain Therapeutics Inc
06/13/20244:38PMEdgar (US Regulatory)Form 424B5 - Prospectus [Rule 424(b)(5)]NASDAQ:GANXGain Therapeutics Inc
05/30/20247:00AMGlobeNewswire Inc.Gain Therapeutics Announces Acceptance of Late-Breaking Abstract for Poster Presentation at Federation of European Neuroscience Societies (FENS) Forum 2024NASDAQ:GANXGain Therapeutics Inc
05/14/20244:06PMEdgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:GANXGain Therapeutics Inc
05/14/20244:03PMEdgar (US Regulatory)Form 8-K - Current reportNASDAQ:GANXGain Therapeutics Inc
05/14/20247:30AMGlobeNewswire Inc.Gain Therapeutics Reports Financial Results for First Quarter 2024 and Provides Corporate UpdateNASDAQ:GANXGain Therapeutics Inc
04/24/20249:25AMGlobeNewswire Inc.Gain Therapeutics Announces Positive Results from the Single Ascending Dose (SAD) Part of the Phase 1 Clinical Trial of GT-02287, a Novel GCase-Targeting Small Molecule Therapy for GBA1 Parkinson’s DiseaseNASDAQ:GANXGain Therapeutics Inc
04/08/20249:25AMGlobeNewswire Inc.Gain Therapeutics Bolsters Management Team with the Appointment of Gene Mack as Chief Financial OfficerNASDAQ:GANXGain Therapeutics Inc
04/01/20249:25AMGlobeNewswire Inc.Gain Therapeutics Strengthens Management Team and Appoints Jonas Hannestad, M.D., Ph.D. as Chief Medical OfficerNASDAQ:GANXGain Therapeutics Inc
03/26/20248:00AMGlobeNewswire Inc.Gain Therapeutics Reports Financial Results for Year End 2023 and Provides Corporate UpdateNASDAQ:GANXGain Therapeutics Inc
03/15/20242:30PMGlobeNewswire Inc.Gain Therapeutics to Present at Public Ventures Discovery DayNASDAQ:GANXGain Therapeutics Inc
03/05/20248:00AMGlobeNewswire Inc.Gain Therapeutics Presents Data at the AD/PD™ 2024 Conference Demonstrating the Mechanism of Action of GT-02287, its Clinical Stage GCase Regulator for the Treatment of Parkinson’s DiseaseNASDAQ:GANXGain Therapeutics Inc
02/27/20242:00PMGlobeNewswire Inc.Gain Therapeutics Announces the Initiation of the Multiple Ascending Dose (MAD) Part of the Phase 1 Clinical Trial of GT-02287, a Novel GCase-targeting Small Molecule Therapy for GBA1 Parkinson’s DiseaseNASDAQ:GANXGain Therapeutics Inc
02/22/20247:00AMEdgar (US Regulatory)Form 8-K - Current reportNASDAQ:GANXGain Therapeutics Inc
02/14/202412:29PMGlobeNewswire Inc.Gain Therapeutics Announces 2024 R&D Update on Parkinson’s Disease with KOL & Analyst InsightNASDAQ:GANXGain Therapeutics Inc
02/06/20249:56AMGlobeNewswire Inc.UPDATE - Gain Therapeutics’ GT-02287 Completely Restores Motor Function in Mouse Models of Parkinson’s DiseaseNASDAQ:GANXGain Therapeutics Inc
02/06/20248:00AMGlobeNewswire Inc.Gain Therapeutics’ GT-02287 Completely Restores Motor Function in Mouse Models of Parkinson’s DiseaseNASDAQ:GANXGain Therapeutics Inc
01/31/20245:26PMEdgar (US Regulatory)Form 8-K - Current reportNASDAQ:GANXGain Therapeutics Inc
01/31/20248:00AMGlobeNewswire Inc.Gain Therapeutics’ CEO Matthias Alder Issues Letter to Shareholders and Provides Operational UpdateNASDAQ:GANXGain Therapeutics Inc
01/02/20244:09PMEdgar (US Regulatory)Form 424B3 - Prospectus [Rule 424(b)(3)]NASDAQ:GANXGain Therapeutics Inc
01/02/20248:00AMGlobeNewswire Inc.Gain Therapeutics Announces Acceptance of Late-Breaking Abstract for Platform Presentation at the 20th Annual WORLDSymposium™ 2024NASDAQ:GANXGain Therapeutics Inc
 Showing the most relevant articles for your search:NASDAQ:GANX

Your Recent History

Delayed Upgrade Clock